---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000033"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:53:30.641831+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics raises ~$100M via private placement; FDA clears IND for CTIM-76

## Summary
- Private placement raises ~$100M gross via 64.5M shares/pre-funded warrants at $1.55/share.
- FDA cleared IND for CTIM-76 (CLDN6 x CD3 bispecific) for Phase 1 in CLDN6-positive gynecologic/testicular cancers.
- First patient enrollment for dose escalation expected mid-2024; Phase 1 study to enroll up to 70 patients.
- Proceeds plus existing cash extend cash runway into 2028, covering estimated Phase 1 trial duration.
- Private placement led by Nextech, with participation from Ally Bridge, Avidity, Blackstone, Blue Owl, etc.

## SEC filing metadata
- accession: 0001842952-24-000033
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000033/0001842952-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000033/cntx-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000033
- JSON: https://secwatch.observer/filing/0001842952-24-000033.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000033.txt

## Key facts
- Material Agreements
  Context Therapeutics Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $100 million (effective 2024-05-01).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the purchasers named therein
  - Value: approximately $100 million
  - Effective: 2024-05-01
  source text: On May 1, 2024, Context Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 59,032,259 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $1.55 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 5,482,741 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $1.549 per Pre-Funded Warrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000033/0001842952-24-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.